JPH08507062A - ヒトにおけるエンテロウイルス感染症の選択的処置のための２−クロロ−１−［［４−［（２，６−ジクロロフェノキシ）メチル］フェニル］メトキシ］−４−メトキシベンゼンの使用 - Google Patents

ヒトにおけるエンテロウイルス感染症の選択的処置のための２−クロロ−１−［［４−［（２，６−ジクロロフェノキシ）メチル］フェニル］メトキシ］−４−メトキシベンゼンの使用

Info

Publication number
JPH08507062A
JPH08507062A JP6519068A JP51906894A JPH08507062A JP H08507062 A JPH08507062 A JP H08507062A JP 6519068 A JP6519068 A JP 6519068A JP 51906894 A JP51906894 A JP 51906894A JP H08507062 A JPH08507062 A JP H08507062A
Authority
JP
Japan
Prior art keywords
formula
enterovirus
humans
pharmaceutical composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6519068A
Other languages
English (en)
Japanese (ja)
Inventor
ロズホン，エドワード・ジェイ
オコンネル，ジョン・エフ
ブオンテンポ，ピーター
コックス，スチュアート・エイ
デマーティノ，ジェイソン・エル
ライト，ジャッケリン・エム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JPH08507062A publication Critical patent/JPH08507062A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
JP6519068A 1993-02-26 1994-02-23 ヒトにおけるエンテロウイルス感染症の選択的処置のための２−クロロ−１−［［４−［（２，６−ジクロロフェノキシ）メチル］フェニル］メトキシ］−４−メトキシベンゼンの使用 Pending JPH08507062A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2352793A 1993-02-26 1993-02-26
US08/023,527 1993-02-26
PCT/US1994/001605 WO1994018960A1 (en) 1993-02-26 1994-02-23 Use of 2-chloro-1-[[4-[(2,6-dichlorophenoxy)methyl]-phenyl]methoxy]-4-methoxy-benzene for the selective treatment of enteroviral infections in humans

Publications (1)

Publication Number Publication Date
JPH08507062A true JPH08507062A (ja) 1996-07-30

Family

ID=21815649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6519068A Pending JPH08507062A (ja) 1993-02-26 1994-02-23 ヒトにおけるエンテロウイルス感染症の選択的処置のための２−クロロ−１−［［４−［（２，６−ジクロロフェノキシ）メチル］フェニル］メトキシ］−４−メトキシベンゼンの使用

Country Status (12)

Country Link
EP (1) EP0686032A1 (enExample)
JP (1) JPH08507062A (enExample)
AU (1) AU691490B2 (enExample)
CA (1) CA2156916A1 (enExample)
FI (1) FI953980L (enExample)
HU (1) HUT72490A (enExample)
IL (1) IL108749A0 (enExample)
MX (1) MXPA94001379A (enExample)
NZ (1) NZ262794A (enExample)
TW (1) TW284686B (enExample)
WO (1) WO1994018960A1 (enExample)
ZA (1) ZA941244B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210244716A1 (en) 2018-10-03 2021-08-12 Jyväskylän Yliopisto Vemurafenib and salts thereof for use in the treatment of enteroviral infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8412799U1 (de) * 1984-04-26 1984-10-31 William Prym-Werke Kg, 5190 Stolberg SB-Verkaufsvorrichtung mit einer als Blisterpackung ausgebildeten Verkaufspackung fuer Fadenlegewerkzeuge wie Stricknadeln
EP0519702A1 (en) * 1991-06-19 1992-12-23 Schering Corporation Orally active antiviral compounds

Also Published As

Publication number Publication date
FI953980A0 (fi) 1995-08-24
HUT72490A (en) 1996-05-28
ZA941244B (en) 1994-08-23
AU691490B2 (en) 1998-05-21
FI953980A7 (fi) 1995-08-24
NZ262794A (en) 1997-03-24
WO1994018960A1 (en) 1994-09-01
MXPA94001379A (es) 2011-09-26
FI953980L (fi) 1995-08-24
TW284686B (enExample) 1996-09-01
EP0686032A1 (en) 1995-12-13
HU9502494D0 (en) 1995-10-30
AU6267994A (en) 1994-09-14
IL108749A0 (en) 1994-05-30
CA2156916A1 (en) 1994-09-01

Similar Documents

Publication Publication Date Title
Tufan et al. COVID-19, immune system response, hyperinflammation and repurposingantirheumatic drugs
EP3912623B1 (en) Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
JPH0676317B2 (ja) 抗ウイルス医薬製剤およびその使用法
JP4627356B2 (ja) ウイルス性心筋炎の予防または治療薬剤
Billah et al. Pharmacology of N-(3, 5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor
CN113747899A (zh) 用于治疗乙型肝炎的Toll样受体激动剂
KR20120044937A (ko) 약학적 제제
CN110433160A (zh) 一种治疗肝纤维化的化合物及其应用
Schonwald Methylprednisolone anaphylaxis
JPH08507062A (ja) ヒトにおけるエンテロウイルス感染症の選択的処置のための２−クロロ−１−［［４−［（２，６−ジクロロフェノキシ）メチル］フェニル］メトキシ］−４−メトキシベンゼンの使用
KR102448406B1 (ko) Ａｅｒｄ/천식에서 트롬복산 수용체 길항제
AU749169B2 (en) A method for preventing the onset of asthma
WO2022024108A1 (en) Ezrin peptide (hep-1) for use in the treatment of coronavirus disease
JP2023524111A (ja) サイトカインストームを治療するための組成物および方法
WO2021224494A1 (en) New treatments of viral infections
US6432961B1 (en) Method for preventing the onset of asthma
Choonara et al. Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia
JP2004002362A (ja) くしゃみ抑制組成物
JPH10330257A (ja) 眼局所用サイトカイン産生抑制剤
WO2005063253A1 (ja) アレルギー症状治療用医薬組成物
CN118831089A (zh) 土贝母皂苷甲在制备调节性t细胞分化抑制剂中的应用
Sovia Emerging Pharmacotherapies for COVID-19
Ohashi Cytokine storm mechanism and treatment in COVID-19
US7449177B2 (en) Remedy for pemphigoid
Mitra et al. Low-Dose inhaled corticosteroid (ICS) confers optimal anti-inflammatory effects, while additional bronchodilator activity is afforded by salmeterol in mild persistent asthmatic children